In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 95464-05-4, name is 1,1′-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex, introducing its new discovery. Quality Control of 1,1′-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex
Bis(azido) compounds of Pd and Pt with bulky phosphine ligands (dppn=1,8-bis(diphenylphosphino)naphthalene, dppf=1,1?-bis(diphenylphosphino)ferrocene, 1-dpn=1-diphenylphosphino-naphthalene): Preparation, structures, and reactivity toward isocyanides
Pd-bis(azido) compounds [Pd(dppn)(N3)2] and [Pd(dppf)(N3)2], which contain bulky chelating bis(phosphine) ligands (dppn=1,8-bis(diphenylphosphino)naphthalene, dppf=1,1?-bis(diphenylphosphino)ferrocene), were prepared from the corresponding chlorides and NaN3. We also prepared the Pt-bis(azido) compound [Pt(1-dpn)(SMe2)(N3)2] containing a bulky monodentate phosphine (1-dpn=1-diphenylphosphino-naphthalene). All these compounds underwent [2+3] cycloaddition with isocyanides (R-NC, R=cyclohexyl, tert-butyl, 2,6-dimethylphenyl) to convert azido ligands to five-membered, C-coordinated tetrazolate rings. In addition, we observed the [Pd(dppn)Cl2]-mediated C-C coupling of PhC{triple bond, short}CH to generate the eta2-PhC{triple bond, short}C-C{triple bond, short}CPh ligand. All compounds have been structurally characterized by X-ray diffraction.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 95464-05-4, and how the biochemistry of the body works.Quality Control of 1,1′-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex
Reference£º
Chapter 1 An introduction to palladium catalysis,
Palladium/carbon catalyst regeneration and mechanical application method